Literature DB >> 25941583

Co-blockade of immune checkpoints and adenosine A2A receptor suppresses metastasis.

Arabella Young1, Deepak Mittal1, Kimberley Stannard2, Michelle Yong2, Michele Wl Teng1, Bertrand Allard3, John Stagg3, Mark J Smyth1.   

Abstract

Immunosuppressive pathways active within the tumor microenvironment must be targeted in combination to sufficiently bolster antitumor immune defenses. Inhibition of A2A adenosine receptor signaling in combination with immune checkpoint blockade enhances CD8+ T and NK cell anti-metastatic activity. This results in reduced metastatic burden and improved survival in pre-clinical models.

Entities:  

Keywords:  PD-1; adenosine; combination therapy; immune checkpoint; metastasis; tumor-mediated immunosuppression

Year:  2014        PMID： 25941583      PMCID： PMC4292728          DOI： 10.4161/21624011.2014.958952

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

1.  Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor.

Authors:  Deepak Mittal; Arabella Young; Kimberley Stannard; Michelle Yong; Michele W L Teng; Bertrand Allard; John Stagg; Mark J Smyth
Journal:  Cancer Res       Date:  2014-07-01       Impact factor: 12.701

2.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

3.  A2A adenosine receptor protects tumors from antitumor T cells.

Authors:  Akio Ohta; Elieser Gorelik; Simon J Prasad; Franca Ronchese; Dmitriy Lukashev; Michael K K Wong; Xiaojun Huang; Sheila Caldwell; Kebin Liu; Patrick Smith; Jiang-Fan Chen; Edwin K Jackson; Sergey Apasov; Scott Abrams; Michail Sitkovsky
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-17       Impact factor: 11.205

4.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

5.  Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis.

Authors:  John Stagg; Upulie Divisekera; Nicole McLaughlin; Janelle Sharkey; Sandra Pommey; Delphine Denoyer; Karen M Dwyer; Mark J Smyth
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-04       Impact factor: 11.205

6.  CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer.

Authors:  Sherene Loi; Sandra Pommey; Benjamin Haibe-Kains; Paul A Beavis; Phillip K Darcy; Mark J Smyth; John Stagg
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-17       Impact factor: 11.205

7.  Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors.

Authors:  Paul A Beavis; Upulie Divisekera; Christophe Paget; Melvyn T Chow; Liza B John; Christel Devaud; Karen Dwyer; John Stagg; Mark J Smyth; Phillip K Darcy
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-20       Impact factor: 11.205

8.  Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.

Authors:  Bertrand Allard; Sandra Pommey; Mark J Smyth; John Stagg
Journal:  Clin Cancer Res       Date:  2013-08-27       Impact factor: 12.531

9.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

10.  Adenosine limits the therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma model.

Authors:  Raffaella Iannone; Lucio Miele; Piera Maiolino; Aldo Pinto; Silvana Morello
Journal:  Am J Cancer Res       Date:  2014-03-01       Impact factor: 6.166
  10 in total
  10 in total

1.  Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma-An exclamation sign with a question mark.

Authors:  Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-06-03       Impact factor: 8.110

Review 2.  A2A adenosine receptor antagonists to weaken the hypoxia-HIF-1α driven immunosuppression and improve immunotherapies of cancer.

Authors:  Stephen M Hatfield; Michail Sitkovsky
Journal:  Curr Opin Pharmacol       Date:  2016-07-17       Impact factor: 5.547

Review 3.  Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.

Authors:  Aitziber Buqué; Norma Bloy; Fernando Aranda; Isabelle Cremer; Alexander Eggermont; Wolf Hervé Fridman; Jitka Fucikova; Jérôme Galon; Radek Spisek; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2016-03-10       Impact factor: 8.110

4.  Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironment.

Authors:  Sara Serra; Tiziana Vaisitti; Valentina Audrito; Cinzia Bologna; Roberta Buonincontri; Shih-Shih Chen; Francesca Arruga; Davide Brusa; Marta Coscia; Ozren Jaksic; Giorgio Inghirami; Davide Rossi; Richard R Furman; Simon C Robson; Gianluca Gaidano; Nicholas Chiorazzi; Silvia Deaglio
Journal:  Blood Adv       Date:  2016-11-22

Review 5.  Tailoring Natural Killer cell immunotherapy to the tumour microenvironment.

Authors:  Alexander David Barrow; Marco Colonna
Journal:  Semin Immunol       Date:  2017-09-19       Impact factor: 11.130

Review 6.  Targeting A2 adenosine receptors in cancer.

Authors:  David Allard; Martin Turcotte; John Stagg
Journal:  Immunol Cell Biol       Date:  2017-02-08       Impact factor: 5.126

Review 7.  Targeting adenosine in cancer immunotherapy: a review of recent progress.

Authors:  Theresa L Whiteside
Journal:  Expert Rev Anticancer Ther       Date:  2017-04-27       Impact factor: 4.512

8.  Cytokine-Induced Killer Cells Express CD39, CD38, CD203a, CD73 Ectoenzymes and P1 Adenosinergic Receptors.

Authors:  Alberto L Horenstein; Antonella Chillemi; Roberta Zini; Valeria Quarona; Nicoletta Bianchi; Rossella Manfredini; Roberto Gambari; Fabio Malavasi; Davide Ferrari
Journal:  Front Pharmacol       Date:  2018-04-20       Impact factor: 5.810

9.  Single Stabilizing Point Mutation Enables High-Resolution Co-Crystal Structures of the Adenosine A2A Receptor with Preladenant Conjugates.

Authors:  Tobias Claff; Tim A Klapschinski; Udaya K Tiruttani Subhramanyam; Victoria J Vaaßen; Jonathan G Schlegel; Christin Vielmuth; Jan H Voß; Jörg Labahn; Christa E Müller
Journal:  Angew Chem Int Ed Engl       Date:  2022-03-24       Impact factor: 16.823

Review 10.  Unleashing Natural Killer Cells in the Tumor Microenvironment-The Next Generation of Immunotherapy?

Authors:  Aviad Ben-Shmuel; Guy Biber; Mira Barda-Saad
Journal:  Front Immunol       Date:  2020-02-21       Impact factor: 7.561
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.